Matrix metalloproteinase-9: A deleterious link between hepatic ischemia-reperfusion and colorectal cancer

Sébastien Lenglet, François Mach, Fabrizio Montecucco

Sébastien Lenglet, François Mach, Fabrizio Montecucco, Cardiology Division, Department of Medicine, Geneva University Hospital, Foundation for Medical Research, 1211 Geneva, Switzerland

Author contributions: Lenglet S wrote the paper; Mach F and Montecucco F approved the final version of the manuscript.

Supported by The Swiss National Science Foundation, No. 32003B-134963/1, to Montecucco F; and EU FP7 AtheroRemo, No. 201668; Swiss National Science Foundation, No. 310030B-133127, to Mach F

Correspondence to: Dr. Fabrizio Montecucco, MD, PhD, Cardiology Division, Department of Medicine, Geneva University Hospital, Foundation for Medical Researches, 64 Avenue Roseraie, 1211 Geneva, Switzerland. fabrizio.montecucco@unige.ch

Telephone: +41-22-3827238 Fax: +41-22-3827245
Received: April 2, 2012 Revised: June 21, 2012 Accepted: July 9, 2012 Published online: December 28, 2012

Abstract

Despite the advent of improved surgical techniques and the development of cytotoxic chemotherapeutic agents useful for the treatment of colorectal cancer, the primary clinical challenge remains that of preventing and combating metastatic spread. Surgical resection is the best treatment for colorectal metastases isolated to the liver. However, in rodent models, the hepatic ischemia-reperfusion (I/R) applied during the surgery accelerates the outgrowth of implanted tumors. Among the adverse effects of I/R on cellular function, several studies have demonstrated an over expression of the matrix metalloproteinase-9 (MMP-9) in the ischemic liver. Since several studies showed high local levels of expression and activity of this proteolytic enzyme in the primary colorectal adenocarcinoma, the role of MMP-9 might be considered as a potential common mediator, favoring both growth of local tumor and the dissemination of colorectal carcinoma metastases.

© 2012 Baishideng. All rights reserved.

Key words: Matrix metalloproteinase-9; Ischemia-reperfusion; Colorectal cancer; Metastasis

Peer reviewers: Takayuki Yamamoto, MD, Inflammatory Bowel Disease Center, Yokkaichi Social Insurance Hospital, 10-8 Hazuyamacho, Yokkaichi 510-0016, Japan; Asmaa Gaber Abdou, Assistant Professor, Department of Pathology, Faculty of Medicine, Menofiya University, Shebein Elkom 002-048, Egypt

Lenglet S, Mach F, Montecucco F. Matrix metalloproteinase-9: A deleterious link between hepatic ischemia-reperfusion and colorectal cancer. World J Gastroenterol 2012; 18(48): 7131-7133 Available from: URL: http://www.wjgnet.com/1007-9327/full/v18/i48/7131.htm DOI: http://dx.doi.org/10.3748/wjg.v18.i48.7131

INTRODUCTION

Colorectal cancer is one of the most commonly diagnosed cancers in developed countries and it is ranked as the second leading cause of death among cancer patients[3]. The majority of these cases is sporadic and develops from a precursor lesion, the adenomatous polyp. At the diagnosis, colorectal cancer is localized to the colon (Dukes A and B stages) in 54% of cases, while it is metastatic to lymph nodes and distant organs (Dukes C and D stages) in the remaining 46%. The survival data demonstrate that the prognosis depends on the severity of the disease: around 80% of patients have long term survival with node negative disease (Dukes A and B stages), this percentage drop to 4% for 5-year survival in patients with metastases (Dukes D stage)[3]. The liver is the most frequent metastatic site of colorectal cancer, and the complete surgical resection of isolated metastases in this organ has been shown to improve disease outcomes[3]. Unfortunately, this therapeutic procedure does not avoid a high rate of metastasis recurrence within the
liver. Experimental evidence accumulated over the last two decades has suggested the association between the increase risk of metastatic relapse and their surgical resection in the liver. Indeed, besides the presence of residual or dormant malignant cells, the blood loss incurred during the operation disseminates colon cancer cells into the peripheral blood. In order to limit the blood loss during the parenchymal resection, surgeons occlude the inflow of blood to the liver.

**HEPATIC ISCHEMIA-REPERFUSION INJURY**

However, hepatic ischemia-reperfusion (I/R) is an additional and strong stimulus that promotes the outgrowth of micrometastases in the liver. Local response to I/R is quite complex, but it can be classified into two distinct phases. The acute hepatocellular injury is caused by reactive oxygen species, intracellular and mitochondrial Ca\(^{2+}\) overload, complement activation and release of cytotoxic cytokines, and is reflected by a rise in plasma liver enzymes. The late phase is characterized by neutrophil infiltration causing further damage to the parenchyma, mainly through a protease-dependent pathway.

In a mouse model of colorectal liver metastases, van der Bilt and colleagues have demonstrated that intermittent clamping prevents both early and late hepatocellular damage and I/R-accelerated tumor growth. These results might be associated with the reduction of neutrophil infiltration in the parenchyma, which contributes to tumor growth by producing proliferation and angiogenesis-stimulating factors and cytokines.

**METALLOPROTEINASE 9 AND COLORECTAL CANCER**

Numerous publications have demonstrated that the disease progression in animal models of tissue invasion and metastasis correlate with enhanced secretion of MMPs by tumor and/or stromal cells. Indeed, the metastatic cascade is characterized by the stromal invasion, "intravasation" of the circulatory system at the primary site, "extravasation" at the secondary site and outgrowth of new tumors. These progressive steps require degradation of the extracellular matrix components by proteolytic enzymes, such as matrix metalloproteinases (MMPs). Increased expression of various isoforms (MMP-1, -2, -3, -7, -9, -12, -13) has been also related with the pathophysiology of the transformation of human neoplastic colorectal mucosa to adenomatous polyps, invasive colorectal cancers, and metastases. Among different MMPs, MMP-9 is of particular interest. Indeed, MMP-9 (also known as gelatinase B) is the main enzyme responsible for the degradation of type IV collagen (a major component of basement membranes) and the denatured collagens (gelatins). Importantly, this capacity of MMP-9 has been previously associated with colorectal cancer progression and dissemination of metastasis. Likewise, this gelatinase might also degrade different matrix substrates including collagen type I, V, VII, X and I, elastin, fibronecetin and laminin. In addition to these extracellular membrane components, MMP-9 cleaves different bioactive molecules, such as growth factors, cytokines, chemokines and also pro-MMPs (pro-MMP-2, pro-MMP-9 and pro-MMP-13) and contributes to transform these molecules into their active forms. Various leukocyte subsets (including neutrophils, monocytes/macrophages and T lymphocytes) produce and release MMP-9.

Although MMP-9 is virtually absent in native livers, it is highly expressed in damaged livers after I/R injury. Its role has been investigated by Hamada and coworkers, using MMP-9 deficient mice and mice treated with a specific neutralizing anti-MMP9 antibody. The authors demonstrated that, when MMP-9 is inhibited, mice were characterized by significant improvement in liver preservation outcomes. This beneficial effect (in both MMP-9 knockout and neutralizing antibody-treated mice) was also associated with a reduction of leukocyte recruitment and cytokine expression within this organ.

Finally, in a next important step, Nicoud and coworkers demonstrated a direct relationship between the hepatic I/R-induced elevations in MMP-9 and the growth of metastatic colorectal carcinoma. To achieve this goal, they have subjected mice to hepatic ischemia after tumor cell injection and treated them with or without doxycycline (a broad-spectrum MMP inhibitor). Mice subjected to 30 min of 70% liver ischemia at the time of the tumor inoculation developed significantly larger tumor (expressed as number and volume), and, concomitantly, they were characterized by elevated MMP-9 levels in the systemic circulation and within liver. Accordingly, treatment with the MMP inhibitor strongly reduced the number and volume of the colorectal carcinoma metastasis in the liver. These results indicate that the inhibition of MMP-9 after the hepatic surgical resection of colorectal carcinoma metastases might be clinically relevant to prevent tumor relapse.

**CONCLUSION**

In summary, these studies have provided important and novel insights on the pivotal role of MMP-9 in the hepatic growth of colorectal carcinoma metastases. Furthermore, a therapeutic strategy targeting the early inhibition of MMP-9 might be a very promising approach to reduce the hepatic metastasis relapse following surgical manipulation of the liver. These preliminary results from basic research also represent a relevant input for developing more selective pharmacological inhibitors of MMP-9 to be tested in vivo in animal models of hepatic cancer dissemination. Although clinical studies investigating the role of MMP-9 in human beings are still lacking, these animal studies might suggest the scientific rationale for future applications targeting MMP-9 activity and expression in cancer care and prevention.
REFERENCES
1 Wittekind C, Neid M. Cancer invasion and metastasis. Oncology 2005; 69 Suppl 1: 14-16
2 Cohen AM, Tremierra S, Candela F, Thaler HT, Sigurdson ER. Prognosis of node-positive colon cancer. Cancer 1991; 67: 1859-1861
3 Brouquet A, Andreou A, Vauthoy JN. The management of solitary colorectal liver metastases. Surgeon 2011; 9: 265-272
4 Koch M, Kienle P, Sauer P, Willeke F, Buhl K, Benner A, Lehnert T, Herfarth C, von Knebel Doeberitz M, Weitz J. Hematogenous tumor cell dissemination during colonoscopy for colorectal cancer. Surg Endosc 2004; 18: 587-591
5 Doi K, Horiuchi T, Uchinami M, Tabo T, Kimura N, Yokomachi J, Yoshida M, Tanaka K. Hepatic ischemia-reperfusion promotes liver metastasis of colon cancer. J Surg Res 2002; 105: 243-247
6 Chen CF, Leu FJ, Chen HI, Wang D. Oxygen radicals and matrix metalloproteinases mediate reperfusion liver injury. Transplant Proc 2005; 37: 4547-4549
7 Coito AJ. Leukocyte transmigration across endothelial and extracellular matrix protein barriers in liver ischemia/reperfusion injury. Curr Opin Organ Transplant 2010 Dec 9; Epub ahead of print
8 van der Bilt JD, Kranenburg O, Nijkamp MW, Smakman N, Veenendaal LM, Te Velde EA, Voest EE, van Diest PJ, Borel Rinkes IH. Ischemia/reperfusion accelerates the outgrowth of hepatic micrometastases in a highly standardized murine model. Hepatology 2005; 42: 165-175
9 Himelstein BP, Canete-Soler R, Bernhard EJ, Dilks DW, Muschel RJ. Metalloproteinases in tumor progression: the contribution of MMP-9. Invasion Metastasis 1994; 14: 246-258
10 Zucker S, Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 2004; 23: 101-117
11 Chu D, Zhao Z, Zhou Y, Li Y, Li J, Zheng J, Zhao Q, Wang W. Matrix metalloproteinase-9 is associated with relapse and prognosis of patients with colorectal cancer. Ann Surg Oncol 2012; 19: 318-325
12 Mook OR, Frederiks WM, Van Noorden CJ. The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta 2004; 1705: 69-89
13 Khandoga A, Kessler JS, Hanschen M, Khandoga AG, Burggraf D, Reichel C, Hamann GF, Enders G, Krombach F. Matrix metalloproteinase-9 promotes neutrophil and cell recruitment and migration in the postischemic liver. J Leukoc Biol 2006; 79: 1295-1305
14 Hamada T, Fondevila C, Busuttil RW, Coito AJ. Metalloproteinase-9 deficiency protects against hepatic ischemia/reperfusion injury. Hepatology 2008; 47: 186-198
15 Nicoud IB, Jones CM, Pierce JM, Earl TM, Matrisian LM, Chari RS, Gorden DL. Warm hepatic ischemia-reperfusion promotes growth of colorectal carcinoma micrometastases in mouse liver via matrix metalloproteinase-9 induction. Cancer Res 2007; 67: 2720-2728

Lenglet S et al. MMP-9 and colorectal cancer